A sole-in-class Biotech player in Oncology and Immunotherapy
Spin-off from the Pasteur Institute in Paris, DIACCURATE is a late preclinical stage biotechnology company which develops “sole-in-class” therapeutics in oncology and immunotherapy.
DIACCURATE is conducting 3 proprietary development programs of highly innovative drug-candidates: the KIF20A inhibitor DIACC2010 disrupts intracellular trafficking to reduce growth of cancer cells while the anti-PLA2G1B antibody DIACC1010 restores CD4 T cells altered functions in cancer and HIV. In the course of 2022, the company will enter its first clinical trial.
Led by Dr. Dominique BRIDON, DIACCURATE was cofounded by Prof. Jacques THÈZE, an international leading authority in the field of CD4 biology and Dr Philippe POULETTY, biotech and medtech pioneer, cofounder and CEO of TRUFFLE CAPITAL.
Dr. Philippe POULETTY, MD
Biotech and Medtech pioneer; Cofounder and CEO of TRUFFLE CAPITAL;
Cofounder & Honorary President of FRANCE BIOTECH;
Former Vice-President of EUROPABIO
Dr. Dominique BRIDON, PhD
Chief Executive Officer
30 years experience in preclinical and clinical development with leadership positions across North America: EPIVAX ONCOLOGY, CONCARLO, BIODESY OPTIVIA, IPSEN, ABBOTT…
Dr. Jérôme TIOLLIER,PhD,
30 years experience in biopharmaceutical R&D;
Former EVP CDO at INNATE PHARMA and European R&D Director of PASTEUR MÉRIEUX Transplant Unit; Cofounder & Chairman of OFU
Prof. Jacques THÈZE, MD, PhD,
Former Head of human immunology department at Pasteur Institute; +250 scientific publications; Corresponding member of the French National Academy of Medicine